Suven Life Sciences granted patents in 9 markets

Suven Life Sciences, a Hyderabad-based biopharmaceutical company specialising in central nervous system (CNS) diseases, on Wednesday said that its clinical candidate for Alzheimer’s disease has secured product patent in India, Mexico, South Africa, Singapore, New Zealand, Korea, Eurasia, Australia and Europe markets. The granted product patent in all these countries is valid till June 2023.

The granted patent for the candidate (SUVN-502), achieved through internal discovery efforts of Suven, has been validated in all the nine member countries of Eurasia (including Russia) and 37 member countries of Europe including major markets like Germany, Switzerland, Denmark, Spain, France, UK, Italy, the Netherlands, Poland, Sweden and Finland, Suven said in a press release.

SUVN-502 completed the Phase-I single ascending and multiple ascending studies at Switzerland and demonstrated to be very safe at all doses tested. The company is planning to initiate the clinical Phase-II proof-of-concept studies during 2010 and is targeting launching the product by end of 2013 or early 2014. Development of GlaxoSmithKline’s molecule, which also falls under the same category, is currently in Phase-II, the release added.

The scrip of Suven Life is currently trading at Rs 29 on the BSE, up 4.88 per cent as against the previous close of Rs 27.65.